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OBJECTIVES We sought to identify characteristic lipid abnormalities in patients with Barth syndrome
(BTHS) and to correlate the lipid profile to phenotype and genotype.
BACKGROUND Barth syndrome typically includes cardiomyopathy, skeletal myopathy, neutropenia, growth
retardation, and 3-methylglutaconic aciduria, and it is commonly associated with mutations
in the tafazzin (TAZ) gene, whose products are homologous to phospholipid acyltransferases.
However, clinical features of BTHS have also been found in patients with normal TAZ gene.
METHODS We analyzed molecular species of phospholipids in left and right ventricle, skeletal muscle,
platelets, lymphoblasts, and fibroblasts from 19 children with BTHS (positive TAZ
mutation), 6 children with BTHS-like syndromes (wild-type TAZ), 4 children with isolated
cardiomyopathy (wild-type TAZ), and various controls.
RESULTS Cardiolipin, the specific lipid found only in mitochondria, was decreased in all tissues from
BTHS patients, whereas concentrations of other phospholipids were normal. The molecular
composition of cardiolipin was altered in all tissues from BTHS patients. The molecular
compositions of phosphatidylcholine and phosphatidylethanolamine were altered in the heart.
Cardiolipin abnormalities were only found in children with true BTHS, not in children with
BTHS-like disease or with isolated cardiomyopathy. The degree of cardiolipin deficiency was
tissue-specific but did not correlate with severity or specific phenotypic expression of BTHS.
CONCLUSIONS Abnormal cardiolipin is a specific diagnostic marker of cardiomyopathies caused by TAZ
mutations. These mutations lead to alterations in the fatty acid composition of several
phospholipids, supporting the idea that TAZ encodes a human acyltransferase. (J Am Coll
Cardiol 2003;42:1994–9) © 2003 by the American College of Cardiology Foundation
Barth syndrome (BTHS) (MIM 302060) is a rare cause of
congestive heart failure in infants. In its typical presen-
tation, it is a multisystem disorder that includes cardio-
myopathy, cyclic neutropenia, growth retardation, prox-
imal and distal muscle weakness, and elevated excretion
of 3-methylglutaconic acid (1– 4). Barth syndrome is an
inherited disease linked to the tafazzin gene (TAZ, G4.5) on
the X chromosome (5–8). Sequence homology of the TAZ
gene with genes coding for phospholipid acyltransferases
triggered speculations that BTHS may be caused by a defect
in phospholipid metabolism (9). This idea was supported by
two observations, namely reduced transfer of linoleic acid
into cardiolipin of BTHS fibroblasts (10), and absence of
tetralinoleoyl-cardiolipin in platelets (11,12), fibroblasts
(13), and muscle tissue (11) from BTHS patients. These
abnormalities are consistent with an acyltransferase defi-
ciency in BTHS, and they raise the question whether the
disease involves other phospholipids besides cardiolipin.
Clinical manifestations of BTHS are extremely variable.
Each symptom may range from mild to severe, generating
vastly different clinical patterns (3,4). Furthermore, cardiac
involvement can present as dilated cardiomyopathy (DCM),
left ventricular noncompaction, or endocardial fibroelastosis
(7,8,14,15). Growth retardation, neutropenia, and muscle
weakness are inconsistently present and may vary in severity.
This makes it difficult to diagnose BTHS on clinical
findings alone and to distinguish BTHS from closely related
diseases, especially other infantile cardiomyopathies. In fact,
some cases of familial cardiomyopathy with all associated
symptoms of BTHS had normal TAZ gene. In one such
case, the BTHS-like disease could be linked to a mutation
of mitochondrial DNA (16), but in other cases the genetic
cause has not yet been identified. The question arises then
as to whether the cardiolipin abnormality described in
BTHS is also present in BTHS-like disease with wild-type
TAZ. Is cardiolipin deficiency strictly the consequence of
TAZ mutations or is it associated with symptoms of BTHS?
If so, does the severity of the symptoms correlate with the
magnitude of cardiolipin deficiency?
METHODS
Patients. The protocols used for harvesting human speci-
mens were approved by the institutional review committees
of New York University Medical Center (platelets), New
York Presbyterian Hospital (heart, skeletal muscle, fibro-
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blasts), Hospital for Special Surgery (platelets, skeletal
muscle), Texas Children’s Hospital (heart), Johns Hopkins
University (lymphoblasts), and the Academic Medical Cen-
ter Amsterdam (fibroblasts). Patients, and/or their guard-
ians, gave written, informed consent in all cases. The study
included children with BTHS, BTHS-like disease, and
isolated cardiomyopathy (Table 1). Children with BTHS
had mutations in the TAZ gene and met either one of the
following clinical criteria: 1) cardiomyopathy plus at least
one noncardiac symptom of BTHS, or 2) no cardiomyop-
athy but at least three noncardiac symptoms of BTHS.
Noncardiac symptoms included neutropenia, growth retar-
dation, proximal and distal skeletal muscle weakness, and
3-methylglutaconic aciduria (15 mg 3-methylglutaconic
acid/g creatinine). Children with BTHS-like disease met
the same clinical criteria as did children with BTHS, but
they did not have TAZ mutations. We also studied three
healthy heterozygous females (42 to 46 years) who carried a
TAZ mutation. Several controls were used in this study.
Cardiac tissue was obtained from six adults with brain death
(22 to 51 years), five adults with ischemic cardiomyopathy
(ICM) (59 to 67 years), and nine adults with DCM (37 to
66 years). Skeletal muscle biopsies were obtained from five
children with Prader-Willi syndrome (2 to 15 years) and
from nine pediatric (1 to 18 years) and four adult (28 to 47
years) patients in whom diagnostic biopsies had shown
minimal nonspecific changes. Platelets were obtained from
five normal children (1 to 15 years) and eight normal adults
(23 to 56 years). All patients were male, unless otherwise
specified.
Abbreviations and Acronyms
BTHS  Barth syndrome
DCM  dilated cardiomyopathy
HPLC  high-performance liquid chromatography
ICM  ischemic cardiomyopathy
LV  left ventricle
RV  right ventricle
TAZ  tafazzin
Table 1. Study Patients
Patient
Specimen
(Age)*
TAZ Mutation
CM NP GR SW MALocation Effect
BTHS
1 RV/LV (0.5) Exon 4 Missense LVNC    
2 LB (1) Exon 8 Missense DCM    
3 FB (1) Intron 2 Frameshift DCM    
4 SM (2), PT (14) Exon 6 Frameshift DCM    
5 LB (3) PT (8) Intron 1 Splice site DCM    
6 FB (3) Exon 4 Missense DCM    
7 FB (4), PT (14) Exon 2 Frameshift DCM    
8 LB (4) Intron 1 Splice site DCM    
9 PT (5) Exon 2 Stopcodon DCM    
10 FB (5) Exon 4 Stopcodon DCM    
11 SM (6), PT (12) Exon 1 Frameshift DCM    
12 PT (6) Exon 8 Missense DCM    
13 PT (7) Exon 2 Frameshift DCM    ND
14 PT (8) Intron 9 Splice site None    
15 LB (9), PT (18) Exon 2 Frameshift DCM    
16 PT (10) Exon 4 Stopcodon None    
17 RV/LV (12) Exon 2 Splice site DCM    
18 PT (15) Exon 2 Splice site EFE    
19 PT (15) Exon 10 Missense DCM    
BTHS-like disease
20 SM (0.3) None None DCM    ND
21 PT (2) None None LVNC    
22 PT (8) None None DCM    
23 PT (9) None None DCM    
24 PT (14) None None None    
25 RV/LV (15) None None DCM    ND
Isolated cardiomyopathy
26 SM (0.1) None None LVNC    
27 LV (11) None None DCM    
28 LV (16) None None DCM    
29 LV (19) None None DCM    
All patients were male, except for Patient 22. *The age (years) at the time of tissue harvest is given in parentheses.
BTHS  Barth syndrome; CM  cardiomyopathy; EFE  endocardial fibroelastosis; FB  fibroblasts; GR  growth
retardation; LB  lymphoblasts; LVNC  left ventricular noncompaction; MA  3-methylglutaconic aciduria; ND  not
determined; NP  neutropenia; PT  platelets; SM  skeletal muscle; SW  skeletal muscle weakness.
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Specimens. Cardiac tissue was excised from whole hearts
explanted for transplantation. Paired samples from the left
ventricle (LV) and right ventricle (RV) were obtained in
most cases. Skeletal muscle biopsies were removed under
surgical conditions. All tissues were frozen in liquid nitrogen
immediately after harvest. Platelets were isolated from antico-
agulated blood by differential centrifugation. Lymphoblasts
and fibroblasts were grown in standard cell culture media. All
samples were stored at 80°C before analysis.
Measurements. Samples were homogenized in aqueous
buffer, and the protein concentration was determined (17).
Lipids were extracted into chloroform/methanol (18) and
separated by two-dimensional thin-layer chromatography
(19). Phospholipids were quantified by the determination of
phosphate after ashing (20). Microanalysis of cardiolipin
was described in detail elsewhere (21). In brief, cardiolipin
was methylated with diazomethane and then derivatized
with naphthylacetic anhydride in the presence of an internal
standard (oleoyl-tristearoyl-cardiolipin). The derivative was
purified by solid-phase extraction and analyzed by high-
performance liquid chromatography (HPLC) with fluores-
cence detector. The concentration of individual cardiolipins
relative to the internal standard was derived from the chro-
matogram by computer-assisted manual peak integration. Mo-
lecular species of phosphatidylcholine and phosphatidyleth-
anolamine were analyzed as 1,2-diacyl-3-dinitrobenzoyl-
glycerol derivatives as described by Takamura et al. (22) with
some modifications (23). The two phospholipids were purified
by thin-layer chromatography, treated with phospholipase C,
and derivatized with 3,5-dinitrobenzoyl chloride. Molecular
species of phosphatidylcholine and phosphatidylethano-
lamine were resolved by reversed-phase HPLC and identi-
fied by fatty acid analysis. Species composition was calcu-
lated from peak integrals of the chromatogram.
Statistics. Data are given as mean  SEM. Study groups
were compared by the Student t test. Both RV and LV were
compared by paired t test. Differences were considered to be
statistically significant for p values below 0.05.
RESULTS
Heart muscle. We compared cardiac tissue from children
with BTHS to cardiac tissue from children with isolated
DCM, as well as adults with DCM, adults with ICM, and
adult organ donors. The non-BTHS groups had similar
lipid composition, and therefore they were considered nor-
Table 2. Phospholipid Composition in BTHS Patients With TAZ Mutation
Specimen
Patient
Group
Phospholipid Composition (mol% Phosphorous)
PC PE CL PI  PS Other
Heart ventricle Control 46.6  0.8 24.4  3.1 11.5  0.2 12.7  0.1 4.6  2.4
BTHS 46.7  1.7 28.5  2.6 5.5  0.5* 12.6  0.6 6.7  1.4
Platelets Control 55.0  0.6 25.0  0.6 0.6  0.1 17.6  0.3 1.8  0.3
BTHS 56.0  1.0 26.0  0.5 0.1  0.1* 16.1  0.4 1.9  0.3
Lymphoblasts Control 44.6  0.5 27.3  2.3 5.4  0.8 14.4  1.6 8.2  1.0
BTHS 43.0  1.2 30.9  1.5 2.8  0.2* 16.7  1.1 6.6  1.3
Four samples were studied in each group. *Significant difference between BTHS and control (p  0.01).
BTHS  Barth syndrome; CL  cardiolipin; PC  phosphatidylcholine; PE  phosphatidylethanolamine; PI 
phosphatidylinositol; PS  phosphatidylserine.
Table 3. Cardiolipin in Heart
Patient Group N Specimen
Cardiolipin Content
(nmol/mg Protein)
Cardiolipin Composition (mol%)
OtherL4 L3O L2O2
Adults
Control 6 LV 12.0  1.3 79.5  2.1 12.1  1.6 4.4  0.7 4.0  0.9
RV 10.3  1.2* 78.0  1.3 13.3  0.8 4.3  0.5 4.4  1.3
ICM 5 LV 8.6  1.3 73.2  3.0 17.0  1.9 5.4  1.1 4.3  0.5
RV 13.5  2.5 79.8  1.4 11.4  0.8 3.5  0.3 5.3  0.9
DCM 9 LV 10.5  0.9 76.4  1.6 14.8  0.8 5.4  0.5 3.3  0.6
RV 12.8  1.4 79.0  1.5 13.2  0.9 4.6  0.6 3.1  0.5
CHF 14 LV 9.8  0.8 75.3  1.5 15.6  0.9 5.4  0.5 3.7  1.6
RV 13.1  1.2* 79.3  1.0* 12.6  0.7* 4.2  1.5* 3.9  1.9
Children
BTHS (TAZ mutation) 2 LV 10.4  3.7 3.5  2.5†‡ 6.7  2.5† 0.1  0.1† 89.8  5.1†‡
RV 6.9  2.9 4.5  3.5† 13.5  9.3 14.8  14.7 67.1  27.7†
BTHS-like disease (normal TAZ) 1 LV 32.4 33.9 4.6 5.2 56.3
RV 9.4 73.7 9.9 0.1 16.3
DCM (normal TAZ) 3 LV 15.2  3.2 80.9  3.9 12.0  2.7 3.5  0.9 3.5  0.4
Patients were male except for one patient in the adult control group and one patient in the adult dilated cardiomyopathy (DCM) group. The congestive heart failure (CHF) group
contained adult patients with ischemic cardiomyopathy (ICM) and DCM. *Significant difference between left ventricle and right ventricle (paired t test, p  0.05). †Significant
difference between Barth syndrome (BTHS) and adult DCM (p  0.001). ‡Significant difference between BTHS and child DCM (p  0.001).
L4  tetralinoleoyl-cardiolipin; L3O  trilinoleoyl-oleoyl-cardiolipin; L2O2  dilinoleoyl-dioleoyl-cardiolipin; TAZ  tafazzin.
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mal controls (data not shown). Cardiac tissue from BTHS
patients contained less cardiolipin than the controls, but all
other phospholipids were present in normal proportions
(Table 2). The molecular composition of cardiolipin was
also abnormal in BTHS. The most striking feature was an
almost complete absence of the predominant molecular
species, tetralinoleoyl-cardiolipin. In contrast, normal levels
of tetralinoleoyl-cardiolipin were found in children without
TAZ mutations, who had either isolated cardiomyopathy or
BTHS-like disease (Table 3). The molecular compositions
of phosphatidylcholine and phosphatidylethanolamine were
also altered in BTHS, with severe deficiency of the
1-palmitoyl-2-arachidonoyl-glycerol species in both phos-
pholipids (Fig. 1). Likewise, a deficiency of arachidonic acid
was noted in phospholipid-bound fatty acids from skeletal
muscle of BTHS patients (data not shown).
Cardiolipin levels from different anatomical sites were
compared. In adult organ donors (control cardiac tissue), the
LV contained 17% more cardiolipin than did the RV and
about twice as much cardiolipin than the atrium (atrial
cardiolipin: 5.8  0.7 nmol/mg protein, n  6). However,
in adult patients with congestive heart failure the RV contained
34% more cardiolipin and 4% more tetralinoleoyl-cardiolipin
than the LV. In BTHS, no consistent difference existed
between RV and LV (Table 3).
Skeletal muscle. Muscle biopsies from children with
BTHS showed extremely low content of cardiolipin, pri-
marily due to deficiency of tetralinoleoyl-cardiolipin. In
contrast, both cardiolipin concentration and cardiolipin
composition were normal in children with other cardiac and
skeletal muscle diseases, including BTHS-like disease (no
TAZ mutation), isolated left ventricular noncompaction,
and Prader-Willi syndrome (Table 4).
Platelets. In children with BTHS, platelets contained very
little cardiolipin but normal amounts of other phospholipids
(Table 2). Cardiolipin deficiency was due to loss of all three
major molecular species (i.e., tetralinoleoyl-cardiolipin,
trilinoleoyl-oleoyl-cardiolipin, and dilinoleoyl-dioleoyl-
cardiolipin). In children with BTHS-like disease (no TAZ
mutation), both cardiolipin total concentration and compo-
sition were normal. Heterozygous carriers of TAZ muta-
tions also had normal cardiolipin (Table 5). In contrast to
heart and skeletal muscle, platelets from BTHS patients did
not show alterations in the fatty acid composition of total
phospholipids (data not shown).
Lymphoblasts and fibroblasts. Cardiolipin was reduced by
about half in lymphoblasts from BTHS patients, whereas all
other phospholipids were normal (Table 2). In fibroblasts,
cardiolipin was reduced by about 75% (0.29  0.05
nmol/mg protein in BTHS vs. 1.22  0.10 nmol/mg
protein in controls, n  4, p  0.001). Although normal
fibroblasts contained very little tetralinoleoyl-cardiolipin
Figure 1. Molecular composition of cardiac phosphatidylcholine (PC) and
phosphatidylethanolamine (PE) from controls and Barth syndrome
(BTHS) patients with tafazzin (TAZ) mutation. Data are means of four
measurements (two left ventricle samples and two right ventricle samples).
Asterisks indicate a statistically significant difference between control and
BTHS (p  0.05). Diacylglycerol species are listed in the sequence in
which they elute from the chromatography column. 16:0  palmitic acid;
18:0 stearic acid; 18:1 oleic acid; 18:2 linoleic acid; 20:4 arachidonic
acid; 22:5  docosapentaenoic acid; 22:6  docosahexaenoic acid.
Table 4. Cardiolipin in Skeletal Muscle
Patient Group N
Cardiolipin Content
(nmol/mg Protein)
Cardiolipin Composition (mol%)
OtherL4 L3O L2O2
Adults
Control 4 1.9  0.3 78.6  2.7 15.8  0.9 4.1  1.1 1.5  0.7
Children
Control 9 2.2  0.3 78.9  2.1 14.7  1.1 3.2  1.1 3.2  0.6
Prader-Willi syndrome 5 1.8  0.1 77.4  0.6 15.8  0.7 5.0  0.2 1.9  0.4
BTHS (TAZ mutation) 2 0.4  0.1* 17.7  2.9* 17.9  11.3 13.5  1.9* 50.9  10.2*
BTHS-like disease (normal TAZ) 1 2.1 78.9 13.3 5.1 2.8
Left ventricular noncompaction (normal TAZ) 1 2.9 80.7 11.4 7.8 0.1
Patients were male except for two patients in the adult control group, four patients in the pediatric control group, and two others in the Prader-Willi group. *Significant difference
between BTHS and child control (p  0.02).
Abbreviations as in Table 3.
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and normal lymphoblasts contained virtually none, the
cardiolipin composition of both cell types changed dramat-
ically in BTHS (data not shown), suggesting that many
cardiolipin species may be affected by the disease.
DISCUSSION
In patients with BTHS, we found abnormal molecular
compositions of several phospholipids, including cardio-
lipin, phosphatidylcholine, and phosphatidylethanolamine.
The data indicate a maldistribution of fatty acids (i.e., fatty
acids lost their preference for specific phospholipids). For
instance, the characteristic predominance of linoleic acid in
cardiolipin was missing in BTHS. Conversely, the content
of linoleoyl was increased in phosphatidylcholine and phos-
phatidylethanolamine. The notion of misdirected fatty acids
was consistent with the presumed acyltransferase defect in
BTHS. The most striking consequence of this defect was
the absence of tetralinoleoyl-cardiolipin, a major molecular
species in several control tissues (24). However, the molec-
ular composition of cardiolipin was altered even in lympho-
blasts that did not contain any tetralinoleoyl-cardiolipin,
suggesting a general impairment of fatty acid trafficking
from and to cardiolipin. In phosphatidylcholine and
phosphatidylethanolamine, deficiency of palmitoyl-
arachidonoyl-glycerol species was the most prominent
abnormality. It was not found in every tissue, but may have
functional implications for eicosanoid-dependent signal
transduction in BTHS hearts.
Barth syndrome varies in its clinical presentation and it is
usually, but not invariably, associated with mutations in the
TAZ gene. Thus, the question arises how phospholipid
abnormalities relate to the various phenotypes and geno-
types. Of 25 children who met clinical criteria of BTHS, we
found abnormal cardiolipin only in the 19 patients with
TAZ mutations. In contrast, neither cardiac or noncardiac
features nor the overall severity of the disease was specifi-
cally linked to cardiolipin deficiency. The absence of phe-
notypic correlation makes it unlikely that the pathophysiol-
ogy of BTHS can be explained solely on the basis of
cardiolipin abnormalities. Instead, there must be additional
factors that modify disease expression.
The association between tetralinoleoyl-cardiolipin defi-
ciency and TAZ mutations suggests that TAZ is involved in
the transfer of linoleoyl groups to cardiolipin. The TAZ
activity is absent in most BTHS patients because the
mutation results in loss of the entire protein. However, in
five of our patients (Patients 1, 2, 6, 12, and 19), we found
missense mutations that cause substitutions of single amino
acids in exons 4, 8, or 10, indicating that these exons are
crucial for acyltransferase activity.
The TAZ mutations can result in a broad spectrum of
cardiac phenotypes, including DCM, left ventricular non-
compaction, and endocardial fibroelastosis (7,8,14,15,25).
Although BTHS with DCM is probably the most charac-
teristic presentation of TAZ mutations, it is clinically
indistinguishable from BTHS-like disorders without TAZ
mutations. Thus, on purely clinical grounds, it is impossible
to differentiate true BTHS from related cardiomyopathies.
We show that cardiolipin is a valuable diagnostic tool to
identify those cardiomyopathies that are caused by TAZ
mutations. Diagnostic cardiolipin analysis in platelets has
become even more attractive since the availability of a rapid
mass-spectrometric technique (12). We propose that cardi-
olipin analysis should be included in the evaluation of all
children with cardiomyopathy in whom X-linked inheri-
tance is suspected.
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